Cargando…

Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients

BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is associated with recurrent hospitalizations and high mortality. Guideline-directed medical therapy (GDMT) reduces morbidity, mortality and re-admission rates. Despite the evidence, less than 50% of patients with HFrEF are prescribed...

Descripción completa

Detalles Bibliográficos
Autores principales: Erickson, Marc, O’Dell, Kimberly, Malpartida, Juan Carlos, Mok, Jacob, Khan, Rafay, Patel, Dharmendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781264/
https://www.ncbi.nlm.nih.gov/pubmed/33447319
http://dx.doi.org/10.14740/cr1169
_version_ 1783631643061256192
author Erickson, Marc
O’Dell, Kimberly
Malpartida, Juan Carlos
Mok, Jacob
Khan, Rafay
Patel, Dharmendra
author_facet Erickson, Marc
O’Dell, Kimberly
Malpartida, Juan Carlos
Mok, Jacob
Khan, Rafay
Patel, Dharmendra
author_sort Erickson, Marc
collection PubMed
description BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is associated with recurrent hospitalizations and high mortality. Guideline-directed medical therapy (GDMT) reduces morbidity, mortality and re-admission rates. Despite the evidence, less than 50% of patients with HFrEF are prescribed appropriate medical therapy. When hospitalized patients have these medications discontinued on admission or during hospitalization, they are less likely to have them restarted on discharge. The goal of this study was to determine the incidence of disruption of beta-blocker (BB) therapy during hospitalization for HFrEF patients admitted to an academic tertiary referral hospital. METHODS: We conducted a retrospective study in a single teaching hospital over the course of 1 year, and utilized data queried from the electronic medical record (EPIC) database. Inclusion criteria were met by patients with an ICD-10 code diagnosis of heart failure, left ventricular ejection fraction less than 40% and BB prescription prior to admission. Additional information noted included age, sex, vital signs throughout the admission and dates where BB was not given for a full 24-h period. Patients in the intensive care unit (ICU) were excluded due to uncertainty of their hemodynamics. Data were extracted from the electronic medical record database and analyzed through Python, Microsoft Excel and RStudio. The incidence of BB disruption during hospitalization was defined as a 24-h period where no BB was administered. Blood pressure (BP) and heart rate (HR) levels were compared between patients who received BB and patients who had a disruption in their BB. Measurements were also obtained to assess whether a correlation exists between holding BB therapy and time of the year, age, or sex. RESULTS: Between January 2018 and January 2019, 780 patient encounters met inclusion criteria for the study. Patients who were continued on BB therapy had an average BP of 120.8/68.7 mm Hg and an HR of 82.4 bpm on days they received their BB. Patients who had a disruption of BB therapy had an average BP of 117.7/67.6 mm Hg and an HR of 88.6 bpm on the days of the disruption (P < 0.001). There was no association between holding BB and age, sex, or time of year. CONCLUSIONS: This study showed that in an academic tertiary referral center, patients with HFrEF who are not in an ICU have a 23% chance of not receiving their recommended BB therapy for 24 h. While the differences measured for BP and HR are statistically significant, they are not clinically significant.
format Online
Article
Text
id pubmed-7781264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-77812642021-01-13 Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients Erickson, Marc O’Dell, Kimberly Malpartida, Juan Carlos Mok, Jacob Khan, Rafay Patel, Dharmendra Cardiol Res Original Article BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is associated with recurrent hospitalizations and high mortality. Guideline-directed medical therapy (GDMT) reduces morbidity, mortality and re-admission rates. Despite the evidence, less than 50% of patients with HFrEF are prescribed appropriate medical therapy. When hospitalized patients have these medications discontinued on admission or during hospitalization, they are less likely to have them restarted on discharge. The goal of this study was to determine the incidence of disruption of beta-blocker (BB) therapy during hospitalization for HFrEF patients admitted to an academic tertiary referral hospital. METHODS: We conducted a retrospective study in a single teaching hospital over the course of 1 year, and utilized data queried from the electronic medical record (EPIC) database. Inclusion criteria were met by patients with an ICD-10 code diagnosis of heart failure, left ventricular ejection fraction less than 40% and BB prescription prior to admission. Additional information noted included age, sex, vital signs throughout the admission and dates where BB was not given for a full 24-h period. Patients in the intensive care unit (ICU) were excluded due to uncertainty of their hemodynamics. Data were extracted from the electronic medical record database and analyzed through Python, Microsoft Excel and RStudio. The incidence of BB disruption during hospitalization was defined as a 24-h period where no BB was administered. Blood pressure (BP) and heart rate (HR) levels were compared between patients who received BB and patients who had a disruption in their BB. Measurements were also obtained to assess whether a correlation exists between holding BB therapy and time of the year, age, or sex. RESULTS: Between January 2018 and January 2019, 780 patient encounters met inclusion criteria for the study. Patients who were continued on BB therapy had an average BP of 120.8/68.7 mm Hg and an HR of 82.4 bpm on days they received their BB. Patients who had a disruption of BB therapy had an average BP of 117.7/67.6 mm Hg and an HR of 88.6 bpm on the days of the disruption (P < 0.001). There was no association between holding BB and age, sex, or time of year. CONCLUSIONS: This study showed that in an academic tertiary referral center, patients with HFrEF who are not in an ICU have a 23% chance of not receiving their recommended BB therapy for 24 h. While the differences measured for BP and HR are statistically significant, they are not clinically significant. Elmer Press 2021-02 2020-12-11 /pmc/articles/PMC7781264/ /pubmed/33447319 http://dx.doi.org/10.14740/cr1169 Text en Copyright 2021, Erickson et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Erickson, Marc
O’Dell, Kimberly
Malpartida, Juan Carlos
Mok, Jacob
Khan, Rafay
Patel, Dharmendra
Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
title Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
title_full Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
title_fullStr Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
title_full_unstemmed Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
title_short Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
title_sort effects of holding beta-blockers on the vital signs of heart failure patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781264/
https://www.ncbi.nlm.nih.gov/pubmed/33447319
http://dx.doi.org/10.14740/cr1169
work_keys_str_mv AT ericksonmarc effectsofholdingbetablockersonthevitalsignsofheartfailurepatients
AT odellkimberly effectsofholdingbetablockersonthevitalsignsofheartfailurepatients
AT malpartidajuancarlos effectsofholdingbetablockersonthevitalsignsofheartfailurepatients
AT mokjacob effectsofholdingbetablockersonthevitalsignsofheartfailurepatients
AT khanrafay effectsofholdingbetablockersonthevitalsignsofheartfailurepatients
AT pateldharmendra effectsofholdingbetablockersonthevitalsignsofheartfailurepatients